Introduction: Ischemia/reperfusion (I/R) of the liver contributes to the pathobiology of liver
Introduction
Hepatic ischemia reperfusion injury (I/R) plays an important role following liver transplantation, liver surgery, and hemorrhagic shock (1) . Evidence has accumulated that TLR4 plays a central role in liver injury and the associated inflammation in warm (2, 3, 4) and cold (5) liver I/R.
Endogenous TLR4 activators such as HMGB1 account for a significant part of TLR4 signaling in liver I/R (4). During LPS signaling, CD14 plays an important role in recognition of LPS by the TLR4/MD2 complex (6) . We have recently shown that CD14 is also required for the recognition of HMGB1 by macrophages (7) . However, the contribution of CD14 to I/R -induced liver injury or inflammation induced by warm I/R is not known. Here, we show CD14 deficiency or neutralization of CD14 suppressed both injury and inflammation in warm liver I/R. Furthermore, CD14 is required for the recognition of exogenous HMGB1 in the setting of I/R. Thus, CD14 is part of the host response to I/R in the liver.
Materials and methods

Reagents
Purified NA/LE rat anti-mouse CD14 antibody were purchased from BD Biosciences (San Jose, CA) and its Isotype control antibody was bought from Biolegend (San Diego, CA). Mouse CD14 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers were from Qiagen (Qiagen Sciences, MD). Mouse Interleukin-6 ELISA kit was from R&D System (Minneapolis, MN).
Mouse sCD14 ELISA kit was purchased from Cellsciences (Canton, MA). HMGB1 ELISA kit was ordered from IBL International (Toronto, Canada). Recombinant mouse HMGB1 was kindly provided by Dr. Kevin Tracey. Anti-mouse CD14 and GADPH primary antibody were purchased from R&D Systems (Minneapolis, MN) and abcam (Cambridge, MA) respectively.
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Animals
CD14 knock-out mice were provided by Dr Mason Freeman and were bred and maintained in the animal facility of the University of Pittsburgh. Wild type control CD57BL/6 mice, C3H/Hej and C3H/HeOuj mice were purchased from Jackson Laboratory (Bar Harbor, Maine). All mice were male, 8 to 12 weeks old and weighed 20 to 30g at the time of the experimental procedures.
Animal handling and care complied with the regulations regarding the care and use of experimental animals published by the National Institutes of Health and was approved by the Institutional Animal Use and Care Committee of the University of Pittsburgh. The animals were maintained in the animal facility with a 12-hour light-dark cycle and free access to standard laboratory chow and water.
Warm hepatic ischemia reperfusion injury
Mice 8-12 weeks old were anesthetized with ketamine (100mg/kg) and Xylazine (10mg/kg) by intraperitoneal injection. After a midline laparotomy, the hepatic lobes were freed by dividing the surrounding ligaments. The vessels supplying to the left side 70% of liver were disrupted by a micro atraumatic vascular clamp, while the blood supply to the remaining liver lobes still remained patent to avoid intestinal venous congestion. The incision was then covered with a piece of saline-soaked gauze, together with a piece of plastic film, to reduce dehydration and mice were placed on a heating pad to maintain a rectal temperature of 37°C. The clamp was subsequently removed after 60 minutes to initiate hepatic reperfusion, and the abdominal incision was closed with running 4-0 Vicryl-plus (Ethicon) sutures. Sham treated mice underwent the same manipulation except the vascular clamp was not applied.
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Sample collection
At the conclusion of the experiment, animals were anesthetized with isoflurane, and blood was harvested by cardiac puncture. Serum was collected by centrifuging the blood at 5,000 revolutions per minute for 10min at 4°C. Serum was aliquoted and stored at -80°C until further analysis. The same left hepatic lobe was harvested and snap-frozen in liquid nitrogen and then stored at -80°C degrees. The liver was also removed and fixed in 10% neutral formalin for Hematoxylin and Eosin (HE) staining. For immunofluoresence staining, liver was flushed with Phosphate-Buffered Saline (PBS) and then perfused with 2% Para formaldehyde. After fixation for 2h, the tissues were switched to 30% sucrose for 24h with sucrose change a total of three times. The samples were cryoperserved in 2-Methylbutane and stored at -80°C until ready for sectioning.
Alanine aminotransferase measurement
Serum alanine aminotransferase was measured with HESKA Dri-Chem 4000 (HESKA; slides from Fujifilm Japan).
RT-PCR
The harvested frozen liver lobes were pulverized and an aliquot of 20-30ug from each mouse was used to extract total RNA with Qiagen RNeasy kit (Qiagen) following the standard protocol.
A total of 1μg RNA was used for cDNA synthesis using iScript™ Reverse Transcription Supermix (Bio-Rad) according to the manufacturer's instructions. Pre-designed CD14 and GAPDH primers from Qiagen were used. PCR was performed on a conventional thermocycler and cycle conditions were as the following: 95°C for 30s, 55°C for 30s, and 72°C for 35s. The PCR products were run on a 1.2% agarose gel to compare the relative intensity semiquantitatively with Adobe Photoshop CS5 (Adobe Systems).
Western blot
Western blot analysis was used to assess CD14 protein levels in whole liver. Fifty micrograms of liver homogenate was separated by SDS-PAGE and transferred onto a nitrocellulose membrane.
The membrane was blocked for 1hr in PBS-Tween (0.1%) with 5% milk, followed by immunostaining with optimized dilutions of a polyclonal rabbit anti-mouse CD14 antibody (1:2,000) in 1% milk in PBS-Tween overnight at 4°C. Horseradish peroxidase-conjugated secondary antibodies were given, and membranes were developed with the Super Signal West Pico chemiluminescent kit (Thermo Fisher Scientific) and exposed to film. GADPH was used as the loading controls for each group.
Enzyme-linked immune sorbent assay (ELISA) for sCD14 and IL-6 sCD14 and IL-6 levels in serum was detected with ELISA kits according to their standard protocols. To measure IL-6 level in liver tissue, liver homogenates were lysed with cell lysis buffer with protease inhibitors added. After centrifugation at full speed for 15min at 4 degree, supernatants were harvested and protein levels were measured with BCA kit. Then the IL-6 level of each ischemic liver was measured by ELISA kit and standardized by its protein concentration. 
Serum HMGB1 level measurement
Serum HMGB1 levels were measured with the HMGB1 ELISA kit developed by Shino-test Corporation according to its standard protocol.
TdT-mediated dUTP digoxigenin nick end labeling assay:
Livers were fixed in 2% paraformaldehyde followed by standardized protocol for 
Histopathology
Liver samples were fixed in 10% formalin and embedded in paraffin, then cut to 6-μm thick sections. Tissues were stained with H&E, and slides were assessed for inflammation and tissue damage.
Statistical analysis
Results are expressed as the mean ± standard error of mean (SEM). We used SigmaPlot performed using the Student's t-test. Significance was established at the 95% confidence (P < 0.05).
Results
CD14 expression increases following warm hepatic I/R
We first assessed the level of CD14 expression in the liver and circulation following liver ischemia and reperfusion. Ischemia alone did not change CD14 mRNA expression from baseline ( Fig. 1a and Fig. 1b ). However, reperfusion induced a marked up-regulation of CD14 mRNA in the liver that was first detected at 1 hour of reperfusion. CD14 protein levels in the ischemic lobe of the liver decreased with the start of ischemia but then increased again between 3 and 6 hours following reperfusion (Fig. 1c) . Control mice showed detectable but low sCD14 levels ( Fig.2) . Ischemia alone did not increase serum sCD14 levels. However, serum sCD14 were significant higher than baseline at 6h and 24h following reperfusion (P<0.01, comparison with baseline levels). These observations show that CD14 gene expression is increased by hepatic I/R and that liver I/R is associated with release of sCD14 into the circulation. It is noteworthy that several cell types in the liver, including hepatocytes express CD14. Total CD14 levels reflect intracellular and cell surface expression of CD14.
CD14 contributes to liver injury following I/R
We next carried out experiments to determine if CD14 contributed to I/R-induced liver injury.
CD14 knockout mice and their wild type counterparts were subjected to 1hr of ischemia followed by 6 or 24hr of reperfusion. There was no difference in ALT levels between wild type and CD14 Knockout sham groups. However, circulating ALT levels were significantly higher in 9 A C C E P T E D Copyright © 2013 by the Shock Society. Unauthorized reproduction of this article is prohibited.
wild type mice subjected to I/R at both 6 and 24hr than CD14 knockout mice (Fig. 3) .
Histological analysis confirmed that CD14 knockout mice were protected from the extensive central lobular necrosis observed at 6 and 24hr in the wild type mice following I/R (Fig. 4) . I/R was also associated with apoptosis assessed by TUNEL staining at 24hr. Here again, CD14 deficiency was associated with the near absence of apoptosis ( Fig. 5a and Fig. 5b ).
To confirm the importance of CD14 to I/R -induced injury we treated wild type mice with a neutralizing anti-CD14 antibody either prior to the onset of ischemia or just prior to reperfusion.
As shown in Fig. 6 , pre-treatment with anti-CD14 antibody significantly attenuated the injury as measured by circulating ALT levels. Administration of antibody just prior to reperfusion had minimal protective effects (Data not shown). Thus, CD14 participates in the pathobiology of I/Rinduced liver injury and most likely is engaged early in the ischemia insult.
CD14 contributes to the inflammatory response after hepatic I/R
I/R -induced liver injury is the result of both ischemic cell death and the inflammatory response that is induced by I/R. To determine if CD14 is involved in I/R-induced inflammation, we measured IL-6 in the liver and circulation as a marker of the inflammatory response. CD14 knockout mice showed much lower elevations in IL-6 in the liver (Fig. 7a) and circulation (Fig.   7b ) than seen in the wild type mice subjected to I/R. Wild type mice pretreated with anti-CD14 antibody also had lower circulating IL-6 levels following I/R (Fig. 7c) . Thus, CD14 is involved in the regulation of I/R -induced inflammation.
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Neutralizing CD14 does not reduce I/R-induced injury in TLR4 deficient mice
We (4) and others (2, 3) have shown that TLR4 is involved in I/R-induced liver damage. Because CD14 is part of the TLR4 receptor complex, we sought evidence that CD14 might participate with TLR4 in liver I/R injury. Anti-CD14 antibody was administered to both wild type and TLR4 mutant mice. As expected, TLR4 mutant mice were partially protected from I/R-induced damage (Fig. 8a) . No further reduction in liver injury was seen by neutralizing CD14 in these mice (Fig. 8b) .
Recombinant HMGB1 given before reperfusion does not increase liver injury in
CD14KO mice
HMGB1 is a prototypical DAMP previously shown to contribute to liver damage in I/R through TLR4. Furthermore, rHMGB1 exacerbates I/R-induced liver damage via a TLR4-dependent mechanism (4). We found no difference in circulating HMGB1 levels between wild type and CD14 KO mice at 6hrs suggesting that CD14 is not required for early HMGB1 release (Fig. 8c) .
We administered 55ug/mouse rHMGB1 (dose based on a pilot study, not shown), which did not result in any detectable liver injury by itself, to both WT and CD14KO mice intraperitoneally.
This dose of HMGB1 did not induce liver injury in control mice. Whereas rHMGB1 worsened liver damage when administered at reperfusion to wild type mice, no increase in damage was seen in CD14 KO mice receiving rHMGB1 (Fig. 8d) . Taken together, these data suggest that CD14 is involved in sensing extracellular HMGB1 in liver I/R.
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Discussion
This study was undertaken to determine if CD14 is involved in I/R-induced liver injury. This question is important because CD14 is known to participate in ligand recognition by the TLR4 receptor complex (6) and TLR4 is involved in the injury and inflammation induced by warm I/R in liver (4). Moreover, recently Li and colleagues reported that I/R could up-regulate CD14 expression in Kupffer cells in rats (8). We show here that CD14 is involved in both the injury and the inflammation induced by liver I/R. Whereas the release of HMGB1 in liver I/R did not require CD14, the recognition of HMGB1 does. These findings suggest that DAMP recognition in liver I/R involves CD14.
CD14, a 55 kDa cell surface glycoprotein that together with Toll-like receptor 4 and MD-2, act as a receptor for endotoxin (6) . CD14 exists in two forms: one is anchored to the cellular membrane by a glycosylphosphatidyl inositol tail, i.e. mCD14, and the other a soluble form (sCD14). mCD14 is mainly expressed on macrophages, neutrophils, and dendritic cells, but epithelial cells(9), endothelial cells(10) and fibroblasts(11) also express low levels of mCD14.
Although mononuclear phagocytes are known to shed their membrane-expressed CD14 (12) and liver can secret CD14 (13), the origin of sCD14 in plasma is not yet totally clear. sCD14 may confer LPS-responsiveness to cells that do not express CD14 (14). Blood and other body fluids contain sCD14, and levels increase during inflammation and infection. Therefore, sCD14 can be regarded as an acute phase protein (15) . Here we show that CD14 mRNA levels in the liver increase after the hepatic I/R and that this corresponds to an increase in circulating sCD14 levels.
It is unclear if the source of this sCD14 is from the liver. These results do indicate that I/R is a potent stimulus for CD14 upregulation and release.
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CD14 knockout mice resist 10 times the LD100 dose of LPS (16) . CD14 neutralizing antibody prevented lethality after in vivo exposure to endotoxin in rabbits and primates (17, 18) .
Neutralizing antibody to mouse CD14 even protects mice sensitized with galactosamine against LPS challenge (19) . Our group found that the essential components for LPS uptake by hepatocytes were CD14, TLR4, MD2, and the beta2-integrin CD11b/CD18 of hepatocytes (20) .
Although LPS is considered as its main ligand, previous studies have shown that CD14 can also recognize other pathogen-associated molecular patterns, including peptidoglycan, lipoteichoic acid (LTA) and lipoarabinomannan (LAM)(21). Recent findings show that CD14 can promote TLR4 endocytosis and interferon expression, and CD14-induced endocytosis occurs independent of TLR4 signaling (22). Moreover, CD14 also enhances TLR2 (23) or TLR3-dependent cellular activation (24). In this study, we have shown that CD14 is actively involved in this sterile model of hepatic I/R injury, and CD14 deficiency or blockade before ischemia attenuates liver injury and inflammatory response in hepatic I/R. Attempts to reduce liver damage through delayed anti-CD14 antibody administration were less successful, suggesting that CD14 is involved in the early events in hepatic I/R.
The proinflammatory properties of HMGB1 were first identified in sepsis models where HMGB1 was show to be a late mediator of lethality (25). In contrast to sepsis, HMGB1 acts as an early mediator in models of sterile inflammation. For example, we have previously shown that HMGB1 contributes to TLR4 dependent signaling in liver I/R and that rHMGB1 exacerbates I/R induced injury in the liver in a TLR4-dependent manner (4) . Here, we show that CD14 is also required for the exacerbation in I/R injury induced by rHMGB1. We have also reported that CD14 is involved in the injury and inflammation in cold cardiac I/R, a model that E. Shows representative WT liver after 1h ischemia+24h reperfusion ( 100).
F. Shows representative CD14KO mice after 1h ischemia+ 24h reperfusion ( 100). 
